BioElectronics Chairman Updates Investors

​​Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharmaFREDERICK, MD – (NewMediaWire) – February 15, 2024 – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic mission is to focus and succeed on three major fronts, these being research, manufacturing processes, and sales. Today, I will focus on the first of these, although I will briefly mention the two other vital components of our mission.CLINICAL TRIALS IN PROGRESSWe have two investigator sponsored clinical trials now in the field. The first is a surgical analgesia trial being conducted at the University of San Diego. This is a major double-blind, randomized assignment study, involving 120 post-surgical patients who have undergone one of eleven different types of surgery often associated with at least moderate pain. Examples are knee and hip arthroplasty, non-mastectomy breast surgery and hernia repair. These patients are being studied for 180 days, with the primary outcome measures being pain levels and opioid consumption measured on postoperative days 1,2,3 and 7 with follow up measures taken on days 14, 21, 28 and 180 days. These latter measures are important since acute surgical pain can turn into chronic pain. Thus, the study will be able to assess the efficacy of our model 088 in not only reducing the acute surgical pain and opioid use, but also reducing or even eliminating any chronic pain resulting from surgery. Such findings will be new to the literature and should provide important evidence on reducing opioid use and minimizing post-surgical chronic pain.The last of the 120 patients was enrolled in October of 2023 and the anticipated end date for this 180-day study is now expected to be March 20, 2024.  For more information: https://clinicaltrials.gov/study/NCT05399355The second study is being conducted at Stanford University Medical Center and is focused on thumb arthritics using a modified version of our 088 model device designed especially for the use around the thumb joint. This double-blind, randomized controlled study will involve 60 subjects who are suffering from arthritic pain in the thumb area of the hand. Like the UCSD study, this four-week study is nearing completion. Interim results on 40 patients have already been analyzed and at least 53 patients have been enrolled. The primary measure for this study is the reduction of pain after 4 weeks. The researchers tell us that they are looking at an April-May time frame to finish the study. Assuming continued favorable results, this study should provide access to a new market for the Company.  For more information: https://clinicaltrials.gov/study/NCT05315297COMPLETED STUDIES NOW UNDER PEER REVIEWThere are two randomized controlled studies that have been completed. The first was an investigator sponsored study to treat chronic post-amputation pain with our nonthermal, pulsed shortwave (radiofrequency) therapy using our model 088 device. This study used a cross-over design where the subject got both the active and sham device for 4 weeks and after each of these four-week periods the subjects record the change in average residual and phantom limb pain.  This study is complete and the results are now in press and will appear in the Regional Anesthesia and Pain Medicine journal.  The abstract will be presented at the American Society of Regional Anesthesia conference in March. Pending publication, we intend to pursue marketing into this pain market given its size (over 1.5 million people have lost a limb). Importantly, up until now there is no effective way of treating phantom limb pain.The second completed double-blind randomized controlled study looked at increasing the quality of life of canines … 

Related Post
Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

BlogofInnovation.com  

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

Recent Posts

Good heart health in middle age may preserve brain function among Black women as they age

​​Research Highlights: Middle-aged Black women with better heart health were less likely to show a decline in mental function compared…

9 hours ago

Revolutionizing Hydration: Alkaline Ionized Water Takes India by Storm

Alkaline ionized water is being widely used in India, signifying a new phase of hydration for consumers with health concerns.…

22 hours ago

MoogleLabs Newest Feat – AI-powered Offensive Language Detection Tool: SwearSwap

MoogleLabs is an organization that is consistently making waves in the world of AI and technology with its innovative solutions…

22 hours ago

iCoreConnect Inc. Announces New State Endorsement of Seven Solutions From the Tennessee Dental Association

​​New Endorsements Allows iCoreConnect New Entry Into the Tennessee MarketOCOEE, FL - (NewMediaWire) - April 23, 2024 - iCoreConnect Inc. (NASDAQ:…

22 hours ago

Ubiquitech Software Corporation Reports Total Convertible Debt Reduction in Excess of $1,700,000 During Past 12 Months

​​DENVER, CO - (NewMediaWire) - April 23, 2024 - Ubiquitech Software Corp. (OTC: UBQU), a trailblazer in innovative software development, is pleased…

1 day ago

Sunknowledge Celebrates 10 Years of Successful Partnership in Providing Medical DME Billing Solutions to Top DME Company in New York

NEW YORK, N.Y., April 23, 2024 (SEND2PRESS NEWSWIRE) — Sunknowledge, a leading provider of healthcare outsourcing solutions, proudly celebrates a…

1 day ago

Seguici

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.